Last reviewed · How we verify
SRK-015
At a glance
| Generic name | SRK-015 |
|---|---|
| Sponsor | Scholar Rock, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy (PHASE2)
- Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD (PHASE2)
- Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese (PHASE2)
- Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam (PHASE3)
- Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab (PHASE3)
- EAP of Apitegromab for Patients With Spinal Muscular Atrophy
- An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SRK-015 CI brief — competitive landscape report
- SRK-015 updates RSS · CI watch RSS
- Scholar Rock, Inc. portfolio CI